Despite SBRT to oligometastatic sites, prostate cancer progression still occurs in a majority of patients due to occult microscopic disease.

The combination of enzalutamide and leuprolide significantly improves overall survival among patients with prostate cancer and a high risk for biochemical recurrence, according to a study published ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by ...

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...

Rural men had almost twice the risk of prostate cancer biochemical recurrence as urban men in the US. Patients living in rural areas may be at an increased risk for prostate cancer biochemical ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...

SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) was a Phase II multi-centre, single arm, non-randomised, open-label copper-64 labelled SAR-Bombesin PET imaging trial of ...

Medicus Pharma is advancing Teverelix, a recently acquired, clinical stage asset, designed to address limitations of current ...

Dr. Jeff Jones, a former U.S. Navy aviator and NASA physician, was diagnosed with prostate cancer after a routine checkup ...

On Monday’s edition of “Closer Look,” Reggie Hicks talked with program host Rose Scott about his efforts to spread awareness ...